Related Experiment Video
Updated: Jun 20, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Serum endocan levels in non-ST segment elevation myocardial infarction patients
Adem Melekoglu1, Alp Giray Aydin1, Uğur Kahveci2
1Sisli Hamidiye Etfal Education and Research Hospital, Emergency Medicine, İstanbul, Türkiye.
Insights
Serum endocan levels were significantly higher in non-ST-segment elevation myocardial infarction patients with significant coronary stenosis. Elevated endocan may indicate endothelial dysfunction and atherosclerotic burden in these patients.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Endothelial Biology
Background:
- Endothelial dysfunction and inflammation are central to acute coronary syndrome (ACS) pathophysiology.
- Endocan is a novel biomarker indicating endothelial activation.
Purpose of the Study:
- To assess serum endocan levels in non-ST-segment elevation myocardial infarction (NSTEMI) patients.
- To determine the association between serum endocan levels and coronary stenosis severity.
Main Methods:
- Prospective observational study of 81 NSTEMI patients undergoing coronary angiography.
- Patients were categorized into groups with clinically significant and non-significant coronary stenosis.
- Serum endocan levels were measured upon admission.
Main Results:
- Serum endocan levels were significantly elevated in patients with significant coronary stenosis (p < 0.001).
- Higher levels of BMI, C-reactive protein (CRP), White Blood Cell (WBC), and Neutrophil Lymphocyte Ratio (NLR) were observed in the significant stenosis group.
- Endocan, BMI, and CRP were independently associated with significant coronary stenosis in multivariate analysis (p < 0.001).
- Receiver operating curve analysis identified an endocan cut-off value > 393.1 ng/L for discriminating significant stenosis (AUC = 0.826).
Conclusions:
- Elevated serum endocan levels are associated with clinically significant coronary stenosis in NSTEMI patients.
- Endocan may serve as a valuable biomarker for endothelial dysfunction and atherosclerotic burden in ACS.
- The findings suggest endocan's potential role in assessing coronary artery disease severity.
Background:
Endothelial dysfunction and inflammation play a key role in the pathophysiology of acute coronary syndrome (ACS). Endocan has emerged as a novel biomarker reflecting endothelial activation.
Objective:
To investigate serum endocan levels in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and their association with coronary stenosis severity.
Methods:
This prospective observational study included 81 NSTEMI patients undergoing coronary angiography. Patients were classified into clinically significant coronary stenosis and non-significant coronary stenosis groups. Serum endocan levels were measured at admission.
Results:
Patients who underwent coronary angiography (n = 81) were divided into two groups as those with clinically significant coronary stenosis (n = 40) and non-significant coronary stenosis (n = 41). Serum endocan levels were significantly higher in the group with clinically significant coronary stenosis (p < 0.001). Mean age and body mass index (BMI) were higher and statistically significant in the group with clinically significant coronary stenosis (p = 0.038, p = 0.042). Inflammation parameters C-reactive protein (CRP), White Blood Cell (WBC) and Neutrophil Lymphocyte ratio (NLR) were higher in the group with clinically significant coronary stenosis (p < 0.001, p = 0.011, p = 0.038). In multivariate logistic regression analysis, endocan (p < 0.001, 95% CI: 1.010-1.035), BMI (p = 0.020, 95% CI: 1.070-2.237), and CRP (p = 0.039, 95% CI: 1.003-1.099) were independently associated with clinically significant coronary stenosis. In Receiver operating curve (ROC) analysis performed to discriminate between patients with and without clinically significant coronary stenosis, the endocan cut-off value was determined as > 393.1 ng/L [p < 0.001, The Area Under the Curve (AUC) = 0.826, 95% CI = 0.732-0.919, Likelihood Ratio + = 7.65, LR - = 0.28].
Conclusion:
Endocan levels are elevated in NSTEMI patients with clinically significant coronary stenosis and may reflect endothelial dysfunction and atherosclerotic burden.
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...